Business Context and Reporting Period
This Form 8-K is a current report filed by OncoCyte Corporation (trading symbol: OCX) on February 23, 2021. The registrant is incorporated in California and its common stock is listed on the NYSE American. The report details significant corporate actions completed in late February 2021, including a major asset acquisition and a planned transfer of stock listing.
Key Financial Metrics and Transaction Details
The filing discloses specific financial terms related to the acquisition of Razor Genomics, Inc. (Razor), but does not provide standard periodic financial metrics such as revenue, profit, cash flow, or debt levels for the reporting period.
- Acquisition Consideration: Total consideration paid to acquire 100% of Razor was $15 million.
- Cash Component: $10 million paid in cash to Encore Clinical, Inc. and minority shareholders.
- Equity Component: 982,318 shares of OncoCyte common stock issued, valued at $5 million based on a five-day average closing price.
- Strategic Asset: The acquisition secures rights to develop and market the lead diagnostic test, DetermaRx.
Material Changes
The filing reports two material changes to the company's status and operations:
- Completion of Acquisition: On February 24, 2021, OncoCyte completed the purchase of all outstanding shares of Razor Genomics, Inc., becoming the sole shareholder. This fulfills obligations under agreements dated September 4, 2019.
- Listing Transfer: On February 23, 2021, the Board of Directors authorized the withdrawal of OncoCyte common stock from the NYSE American and initiated an application to list on the Nasdaq Stock Market.
Guidance, Outlook, and Risks
The filing contains standard forward-looking statements regarding the acquisition and listing transfer. Management directs investors to the "Risk Factors" section of the company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q for additional factors that could cause actual results to differ from anticipated outcomes. The company disclaims any obligation to update these forward-looking statements.
Regarding the equity issuance for the Razor acquisition, the shares were issued without registration under the Securities Act of 1933, relying on exemptions under Section 4(a)(2) and Rule 506.
Investor Verification Checklist
- Verify the completion of the Razor Genomics acquisition and the integration of the DetermaRx diagnostic test into OncoCyte's portfolio.
- Confirm the status of the stock listing transfer from NYSE American to the Nasdaq Stock Market.
- Review the impact of the $10 million cash outflow and the issuance of 982,318 new shares on the company's liquidity and shareholder dilution.
- Examine the press releases (Exhibits 99.1 and 99.2) referenced in the filing for further details on the strategic rationale.